Cargando…
Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
SARS-CoV-2 variants could induce immune escape by mutations on the receptor-binding domain (RBD) and N-terminal domain (NTD). Here we report the humoral immune response to circulating SARS-CoV-2 variants, such as 501Y.V2 (B.1.351), of the plasma and neutralizing antibodies (NAbs) elicited by CoronaV...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138844/ https://www.ncbi.nlm.nih.gov/pubmed/34021265 http://dx.doi.org/10.1038/s41422-021-00514-9 |
_version_ | 1783695888374300672 |
---|---|
author | Cao, Yunlong Yisimayi, Ayijiang Bai, Yali Huang, Weijin Li, Xiaofeng Zhang, Zhiying Yuan, Tianjiao An, Ran Wang, Jing Xiao, Tianhe Du, Shuo Ma, Wenping Song, Liyang Li, Yongzheng Li, Xiang Song, Weiliang Wu, Jiajing Liu, Shuo Li, Xuemei Zhang, Yonghong Su, Bin Guo, Xianghua Wei, Yangyang Gao, Chuanping Zhang, Nana Zhang, Yifei Dou, Yang Xu, Xiaoyu Shi, Rui Lu, Bai Jin, Ronghua Ma, Yingmin Qin, Chengfeng Wang, Youchun Feng, Yingmei Xiao, Junyu Xie, Xiaoliang Sunney |
author_facet | Cao, Yunlong Yisimayi, Ayijiang Bai, Yali Huang, Weijin Li, Xiaofeng Zhang, Zhiying Yuan, Tianjiao An, Ran Wang, Jing Xiao, Tianhe Du, Shuo Ma, Wenping Song, Liyang Li, Yongzheng Li, Xiang Song, Weiliang Wu, Jiajing Liu, Shuo Li, Xuemei Zhang, Yonghong Su, Bin Guo, Xianghua Wei, Yangyang Gao, Chuanping Zhang, Nana Zhang, Yifei Dou, Yang Xu, Xiaoyu Shi, Rui Lu, Bai Jin, Ronghua Ma, Yingmin Qin, Chengfeng Wang, Youchun Feng, Yingmei Xiao, Junyu Xie, Xiaoliang Sunney |
author_sort | Cao, Yunlong |
collection | PubMed |
description | SARS-CoV-2 variants could induce immune escape by mutations on the receptor-binding domain (RBD) and N-terminal domain (NTD). Here we report the humoral immune response to circulating SARS-CoV-2 variants, such as 501Y.V2 (B.1.351), of the plasma and neutralizing antibodies (NAbs) elicited by CoronaVac (inactivated vaccine), ZF2001 (RBD-subunit vaccine) and natural infection. Among 86 potent NAbs identified by high-throughput single-cell VDJ sequencing of peripheral blood mononuclear cells from vaccinees and convalescents, near half anti-RBD NAbs showed major neutralization reductions against the K417N/E484K/N501Y mutation combination, with E484K being the dominant cause. VH3-53/VH3-66 recurrent antibodies respond differently to RBD variants, and K417N compromises the majority of neutralizing activity through reduced polar contacts with complementarity determining regions. In contrast, the 242–244 deletion (242–244Δ) would abolish most neutralization activity of anti-NTD NAbs by interrupting the conformation of NTD antigenic supersite, indicating a much less diversity of anti-NTD NAbs than anti-RBD NAbs. Plasma of convalescents and CoronaVac vaccinees displayed comparable neutralization reductions against pseudo- and authentic 501Y.V2 variants, mainly caused by E484K/N501Y and 242–244Δ, with the effects being additive. Importantly, RBD-subunit vaccinees exhibit markedly higher tolerance to 501Y.V2 than convalescents, since the elicited anti-RBD NAbs display a high diversity and are unaffected by NTD mutations. Moreover, an extended gap between the third and second doses of ZF2001 leads to better neutralizing activity and tolerance to 501Y.V2 than the standard three-dose administration. Together, these results suggest that the deployment of RBD-vaccines, through a third-dose boost, may be ideal for combating SARS-CoV-2 variants when necessary, especially for those carrying mutations that disrupt the NTD supersite. |
format | Online Article Text |
id | pubmed-8138844 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-81388442021-05-21 Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines Cao, Yunlong Yisimayi, Ayijiang Bai, Yali Huang, Weijin Li, Xiaofeng Zhang, Zhiying Yuan, Tianjiao An, Ran Wang, Jing Xiao, Tianhe Du, Shuo Ma, Wenping Song, Liyang Li, Yongzheng Li, Xiang Song, Weiliang Wu, Jiajing Liu, Shuo Li, Xuemei Zhang, Yonghong Su, Bin Guo, Xianghua Wei, Yangyang Gao, Chuanping Zhang, Nana Zhang, Yifei Dou, Yang Xu, Xiaoyu Shi, Rui Lu, Bai Jin, Ronghua Ma, Yingmin Qin, Chengfeng Wang, Youchun Feng, Yingmei Xiao, Junyu Xie, Xiaoliang Sunney Cell Res Article SARS-CoV-2 variants could induce immune escape by mutations on the receptor-binding domain (RBD) and N-terminal domain (NTD). Here we report the humoral immune response to circulating SARS-CoV-2 variants, such as 501Y.V2 (B.1.351), of the plasma and neutralizing antibodies (NAbs) elicited by CoronaVac (inactivated vaccine), ZF2001 (RBD-subunit vaccine) and natural infection. Among 86 potent NAbs identified by high-throughput single-cell VDJ sequencing of peripheral blood mononuclear cells from vaccinees and convalescents, near half anti-RBD NAbs showed major neutralization reductions against the K417N/E484K/N501Y mutation combination, with E484K being the dominant cause. VH3-53/VH3-66 recurrent antibodies respond differently to RBD variants, and K417N compromises the majority of neutralizing activity through reduced polar contacts with complementarity determining regions. In contrast, the 242–244 deletion (242–244Δ) would abolish most neutralization activity of anti-NTD NAbs by interrupting the conformation of NTD antigenic supersite, indicating a much less diversity of anti-NTD NAbs than anti-RBD NAbs. Plasma of convalescents and CoronaVac vaccinees displayed comparable neutralization reductions against pseudo- and authentic 501Y.V2 variants, mainly caused by E484K/N501Y and 242–244Δ, with the effects being additive. Importantly, RBD-subunit vaccinees exhibit markedly higher tolerance to 501Y.V2 than convalescents, since the elicited anti-RBD NAbs display a high diversity and are unaffected by NTD mutations. Moreover, an extended gap between the third and second doses of ZF2001 leads to better neutralizing activity and tolerance to 501Y.V2 than the standard three-dose administration. Together, these results suggest that the deployment of RBD-vaccines, through a third-dose boost, may be ideal for combating SARS-CoV-2 variants when necessary, especially for those carrying mutations that disrupt the NTD supersite. Springer Singapore 2021-05-21 2021-07 /pmc/articles/PMC8138844/ /pubmed/34021265 http://dx.doi.org/10.1038/s41422-021-00514-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Cao, Yunlong Yisimayi, Ayijiang Bai, Yali Huang, Weijin Li, Xiaofeng Zhang, Zhiying Yuan, Tianjiao An, Ran Wang, Jing Xiao, Tianhe Du, Shuo Ma, Wenping Song, Liyang Li, Yongzheng Li, Xiang Song, Weiliang Wu, Jiajing Liu, Shuo Li, Xuemei Zhang, Yonghong Su, Bin Guo, Xianghua Wei, Yangyang Gao, Chuanping Zhang, Nana Zhang, Yifei Dou, Yang Xu, Xiaoyu Shi, Rui Lu, Bai Jin, Ronghua Ma, Yingmin Qin, Chengfeng Wang, Youchun Feng, Yingmei Xiao, Junyu Xie, Xiaoliang Sunney Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines |
title | Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines |
title_full | Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines |
title_fullStr | Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines |
title_full_unstemmed | Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines |
title_short | Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines |
title_sort | humoral immune response to circulating sars-cov-2 variants elicited by inactivated and rbd-subunit vaccines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138844/ https://www.ncbi.nlm.nih.gov/pubmed/34021265 http://dx.doi.org/10.1038/s41422-021-00514-9 |
work_keys_str_mv | AT caoyunlong humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT yisimayiayijiang humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT baiyali humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT huangweijin humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT lixiaofeng humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT zhangzhiying humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT yuantianjiao humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT anran humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT wangjing humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT xiaotianhe humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT dushuo humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT mawenping humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT songliyang humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT liyongzheng humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT lixiang humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT songweiliang humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT wujiajing humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT liushuo humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT lixuemei humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT zhangyonghong humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT subin humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT guoxianghua humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT weiyangyang humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT gaochuanping humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT zhangnana humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT zhangyifei humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT douyang humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT xuxiaoyu humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT shirui humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT lubai humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT jinronghua humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT mayingmin humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT qinchengfeng humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT wangyouchun humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT fengyingmei humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT xiaojunyu humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines AT xiexiaoliangsunney humoralimmuneresponsetocirculatingsarscov2variantselicitedbyinactivatedandrbdsubunitvaccines |